A detailed history of Guggenheim Capital LLC transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 24,984 shares of SWTX stock, worth $919,661. This represents 0.01% of its overall portfolio holdings.

Number of Shares
24,984
Previous 19,185 30.23%
Holding current value
$919,661
Previous $722,000 10.8%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$32.04 - $42.76 $185,799 - $247,965
5,799 Added 30.23%
24,984 $800,000
Q2 2024

Aug 14, 2024

BUY
$36.06 - $47.62 $691,811 - $913,589
19,185 New
19,185 $722,000
Q2 2022

Aug 15, 2022

SELL
$18.36 - $60.07 $66,040 - $216,071
-3,597 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$48.97 - $65.46 $12,879 - $17,215
263 Added 7.89%
3,597 $203,000
Q4 2021

Feb 14, 2022

BUY
$53.3 - $75.84 $177,702 - $252,850
3,334 New
3,334 $207,000

Others Institutions Holding SWTX

About SpringWorks Therapeutics, Inc.


  • Ticker SWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,401,100
  • Market Cap $2.3B
  • Description
  • SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...
More about SWTX
Track This Portfolio

Track Guggenheim Capital LLC Portfolio

Follow Guggenheim Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.